Dose considerations for anti‐cancer drugs in metastatic prostate cancer

Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug‐specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under‐exposure of docetaxel and cabazitaxel; over‐exposure of enzalutamide; and varied absorption of abiraterone acetate.